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During the first 12 months of an emergency meningococ-
cal ACWY vaccination program for teenagers in England, 
coverage among persons who left school in 2015, the first 
cohort to be vaccinated, was 36.6%. There were 69% few-
er group W meningococcal cases than predicted by trend 
analysis and no cases in vaccinated teenagers.
Several countries in Europe, South America, and Aus-tralia are experiencing outbreaks of group W meningo-
coccal (MenW) disease, caused by a hypervirulent strain 
of Neisseria meningitides belonging to sequence type 11 
(ST11) clonal complex (CC) and associated with severe 
disease and a high case-fatality rate (1). In England, MenW 
cases caused predominantly by ST11 increased from 19 in 
epidemiologic year 2008–09 to 176 in 2014–15, which rep-
resented 2% and 24%, respectively, of all invasive menin-
gococcal disease (IMD) cases (2).
In response to the national increase in MenW cases in 
England, an emergency immunization program with me-
ningococcal ACWY conjugate vaccine (MenACWY) for 
adolescents was started in August 2015 (3). This program 
replaced the MenC program for children 13–14 years of 
age, and there was also a 2-year phased catch-up program 
for persons 14–18 years of age as of August 31, 2015 (Table 
1) (3). Vaccine was also offered to new university entrants 
<25 years of age.  Compared with persons of the same age 
who do not attend university, new university entrants have 
a higher risk for IMD, likely because of social factors that 
increase meningococcal transmission (4). This single-dose 
vaccination program aimed to directly protect vaccine-el-
igible cohorts and, in the long term, indirectly protect the 
wider population by reducing meningococcal carriage (5).
Students in the target group who left secondary school 
in the summer of 2015 and were 18 years of age before 
September 2015 were the first cohort offered the vaccine 
through general medical practices, starting in August 2015. 
Nearly one third of this cohort were accepted into universi-
ties in 2015 (6). We report impact and vaccine effective-
ness data for the first 12 months of the MenACWY pro-
gram in England.
The Study
Public Health England conducts enhanced national IMD 
surveillance in England, where 84% of the UK population 
resides. National Health Service hospital laboratories rou-
tinely submit local invasive meningococcal isolates to the 
Public Health England Meningococcal Reference Unit for 
confirmation and characterization, with national PCR test-
ing also offered (7). Confirmed case-patients are routinely 
followed up for additional details, including vaccination 
history and outcome (8).
We assessed whether MenACWY vaccine cover-
age might be higher among new university entrants. We 
compared vaccine coverage in June 2016 estimated from 
data automatically extracted from primary care databas-
es in university-affiliated (n = 79) medical practices on a 
university campus or recommended by the university on 
their website and non–university-affiliated (n = 7,543) 
general medical practices for persons who left school 
in 2015.
To estimate vaccine impact, we compared confirmed 
MenW, MenY, and MenB cases in persons who left 
school in 2015 with projected cases for the first academic 
year (September 2015–August 2016) after program intro-
duction. To estimate projected case numbers for 2015–16 
in the absence of vaccination, we fitted a Poisson regres-
sion model with age and time-trend parameters for case-
patients 19–24 years of age during 2010–11 and 2015–16 
who were not in vaccine-targeted cohorts. We used this 
model to estimate case projections and incidence rate ra-
tios, which are presented as percentage decrease (1 – in-
cidence rate ratio). MenC cases were excluded because of 
successful MenC vaccination programs for persons 14–16 
years of age and new university entrants available since 
September 2013.
We assessed vaccine effectiveness among persons 
who left school during the 2015–16 academic year. Vac-
cine effectiveness was estimated by using the screening 
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method (9). Vaccine coverage in cases was compared 
with population vaccination coverage in age-matched 
peers in England (10).
MenW cases in England increased overall by 15%, 
from 189 in the 2014–15 academic year to 218 in 2015–16. 
Isolates were available for 178 culture-confirmed cases in 
2015–16; a total of 155 (87%) were ST11 CC. Case num-
bers and incidence increased in every age group except per-
sons 15–19 years of age (26 to 18 cases; 31% reduction) 
and infants <1 year of age (26 to 17 cases; 35% reduction) 
(Table 2). Six (33%) of 18 teenage case-patients died, but 
no infant case-patients died.
By June 2016, vaccine coverage in persons who left 
school was 36.6%; a total of 79% of these vaccinations 
were administered during August–September 2015. Vac-
cine coverage among persons who left school was higher 
in university-affiliated medical practices than in non–
university-affiliated medical practices (56.1% vs. 33.8%; 
p<0.0001) (Figure 1).
During the first 12 months of the MenACWY vaccina-
tion program for teenagers, there were 6 confirmed MenW 
cases among ≈650,000 persons who left school compared 
with a projected 19.4 cases (69% decrease, 95% CI 18%–
88%), (Figure 2). Five of the 6 cases had ST11 CC (3 were 
confirmed by PCR only, and ST11 CC war inferred for 
PorA P1.5.2). None of these 6 eligible case-patients had 
received MenACWY vaccine, and only 1 (a student from 
overseas who was not vaccinated) was in a university set-
ting. On the basis of population coverage of 36.6% among 
persons who left school, early estimated vaccine effective-
ness was 100% (95% CI −47% to 100%), but CIs were 
wide because of small numbers.
One case each of MenY and MenC disease were di-
agnosed in persons (both not vaccinated) who left school 
during 2015–16 compared with 3 of each in 2014–15. 
MenB cases increased from 10 in 2014–15 to 17 in 2015–
16. Of the 17 case-patients in 2015–16, six (35%) had 
received MenACWY vaccine, consistent with national 
vaccine coverage.
Conclusions
We found a major reduction (69%) in observed MenW 
cases compared with predicted MenW cases among the 
first cohort in England to be offered MenACWY conjugate 
vaccine after the first year of an emergency vaccination 
program for teenagers, even with a small number of cases. 
This decrease occurred despite national vaccine coverage 
of only 36.6% for this cohort. All case-patients who left 
school in 2015 and had confirmed MenW disease were not 
vaccinated; the only university case was in an overseas 
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Table 1. Scheduling of meningococcal ACWY vaccination routines and 3-year catch-up vaccination programs, England* 
Birth cohort 
School year (age, y, at end of 2014–15 
academic year on 2015 Aug 31) 
Earliest school year at time of vaccination and type of vaccine 
received 
2014–15 2015–16 2016–17 2017–18 
2003 Sep 1–2004 Aug 31 6 (11) NA NA NA Y9 ACWY† 
2002 Sep 1–2003 Aug 31 7 (12) NA NA Y9 ACWY† ‡ 
2001 Sep 1–2002 Aug 31 8 (13) NA Y9 ACWY† ‡ ‡ 
2000 Sep 1–2001 Aug 31 9 (14) Y9 MenC§ NA Y11 ACWY¶ ‡ 
1999 Sep 1–2000 Aug 31 10 (15) NA Y11 ACWY¶ ‡ ‡ 
1998 Sep 1–1999 Aug 31 11 (16) NA NA Y13 ACWY# ‡ 
1997 Sep 1–1998 Aug 31 12 (17) NA Y13 ACWY# ‡ ‡ 
1996 Sep 1–1997 Aug 31 13 (18; those who left school in 2015) Y13 ACWY# ‡ ‡ ‡ 
*NA, not applicable; Y, year. 
†New routine schedule MenACWY vaccination. 
‡Completed MenACWY vaccination of cohort. 
§Routine schedule MenC vaccination. 
¶School-based MenACWY catch-up cohorts. 
#General medical practice–based MenACWY catch-up cohorts. 
 
 
 
 
 
 
Table 2. Age distribution of laboratory-confirmed cases of group W meningococcal infection in students, by academic year, England, 
2010–11 to 2015–16* 
Age 
group, y 
Academic year 
2010–11 2011–12 2012–13 2013–14 2014–15 2015–16 
No. 
cases Incidence 
No. 
cases Incidence 
No. 
cases Incidence 
No. 
cases Incidence 
No. 
cases Incidence 
No. 
cases Incidence 
<1 3 0.45 4 0.59 3 0.43 12 1.77 26 3.91 17 2.56 
1–4 8 0.31 6 0.23 5 0.19 5 0.18 22 0.80 26 0.94 
5–14 1 0.02 1 0.02 3 0.05 1 0.02 4 0.06 7 0.11 
15–19 4 0.12 1 0.03 13 0.40 13 0.40 26 0.80 18 0.56 
20–24 3 0.09 1 0.03 3 0.08 7 0.19 6 0.17 18 0.50 
25–44 1 0.01 3 0.02 6 0.04 6 0.04 7 0.05 10 0.07 
45–64 7 0.05 6 0.04 13 0.10 12 0.09 29 0.21 43 0.31 
>65 11 0.13 11 0.13 15 0.17 34 0.37 69 0.72 79 0.81 
Total 38 0.07 33 0.06 61 0.11 90 0.17 189 0.35 218 0.40 
*Academic years are September 1–August 31. Incidence, cases/100,000 population. 
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student who was not vaccinated. Higher vaccine cover-
age among university-affiliated general medical practices 
suggests that persons who left school and were enrolled in 
universities were more likely to be vaccinated than age-
matched peers who did not seek higher education. Some 
universities have actively vaccinated new entrants and 
achieved high uptake rates (11).
Our initial data on vaccine effectiveness and effect 
on disease among persons who left school in 2015 are 
encouraging. However, continued surveillance is vital. 
Multicomponent MenB vaccine 4CMenB (Bexsero, Ba-
sel, Switzerland) was added to the UK national infant vac-
cination program for infants in September 2015 (12). Un-
like conjugated polysaccharide meningococcal vaccines, 
4CMenB is not capsule specific and has the potential to 
offer broader protection against all meningococcal strains. 
Antibodies from 4CMenB-vaccinated infants showed 
potent serum bactericidal antibody activity against the hy-
pervirulent MenW ST11 strain (13), which is consistent 
with the observed decrease in MenW cases among infants.
Public Health England will continue to monitor ef-
fects of vaccination programs as more cohorts are vac-
cinated. Younger cohorts are receiving MenACWY con-
jugate vaccine through a school-based program; uptake 
rates are much higher (72%–84%) than for persons who 
left school and were vaccinated through general medical 
practices (14). Although overall MenW cases increased 
in 2015–16 compared with 2014–15, the proportionate 
increase in cases was lower than in previous years, when 
cases were nearly doubling every year. Whether this find-
ing indicates early signs of an indirect effect is specula-
tive, but 4 months into the 2016–17 academic year, total 
MenW case numbers are only 8% higher than at the same 
time in 2015–16.
By the autumn of 2017, MenACWY vaccine will 
have been offered to all targeted teenagers in the United 
Kingdom. Because this group also has the highest me-
ningococcal carriage rates (15), we hope that prevent-
ing carriage through vaccination will reduce cases and 
deaths in unvaccinated cohorts across all age groups in 
the coming years.
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etymologia
Meningococcal [mə-ningʺgo-kokʹal] Disease
Ronnie Henry
From the Greek meninx (“membrane”) + kokkos (“berry”), me-ningococcal disease was first described by Vieusseux during 
an outbreak in Geneva in 1805. In 1884, Italian pathologists Ettore 
Marchiafava and Angelo Celli described intracellular micrococci in 
cerebrospinal fluid, and in 1887, Anton Wiechselbaum identified the 
meningococcus (designated as Diplococcus intracellularis menin-
gitidis) in cerebrospinal fluid and established the connection between 
the organism and epidemic meningitis. Meningococcus can cause 
endemic cases, clusters, and epidemics of meningitis and septicemia.
Areas with 
frequent 
epidemics of 
meningococcal 
meningitis. 
Data source:  
World Health 
Organization, 
Geneva, 
Switzerland, 
2012.
